Aligos Therapeutics, Inc. Shareholders' Equity
Aligos Therapeutics, Inc. (ALGS) had Shareholders' Equity of $31.88 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-06
- 2026-06-30: Stockholders' Equity Attributable to Parent $31.88M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $31.79M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $53.55M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $71.83M.
| Period end | Stockholders' Equity Attributable to Parent | Stockholders' Equity Attributable to Parent as first filed |
|---|---|---|
| 2026-06-30 | $31.88M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $31.79M 10-Q · filed 2026-08-06 | |
| 2025-12-31 | $53.55M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $71.83M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $101.87M 10-Q · filed 2026-08-06 | |
| 2025-03-31 | $116.44M 10-Q · filed 2026-08-06 | |
| 2024-12-31 | -$28.97M 10-Q · filed 2026-08-06 | |
| 2024-09-30 | $50.10M 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $67.23M 10-Q · filed 2025-11-06 | |
| 2024-03-31 | $59.80M 10-Q · filed 2025-11-06 | |
| 2023-12-31 | $92.08M 10-K · filed 2026-03-05 | |
| 2023-09-30 | $54.82M 10-Q · filed 2024-11-06 | |
| 2023-06-30 | $69.64M 10-Q · filed 2024-11-06 | |
| 2023-03-31 | $84.75M 10-Q · filed 2024-08-06 | |
| 2022-12-31 | $103.90M 10-K · filed 2025-03-10 | |
| 2022-09-30 | $122.01M 10-Q · filed 2023-11-02 | |
| 2022-06-30 | $136.98M 10-Q · filed 2023-11-02 | |
| 2022-03-31 | $152.89M 10-Q · filed 2023-08-03 | |
| 2021-12-31 | $184.73M 10-K · filed 2024-03-12 | |
| 2021-09-30 | $217.01M 10-Q · filed 2022-11-02 | |
| 2021-06-30 | $168.88M 10-Q · filed 2022-11-02 | $168.88M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $195.22M 10-Q · filed 2022-08-04 | |
| 2020-12-31 | $220.04M 10-K · filed 2023-03-09 | |
| 2020-09-30 | -$136.67M 10-Q · filed 2021-11-04 | |
| 2020-06-30 | -$104.57M 10-Q · filed 2021-11-04 | |
| 2020-03-31 | -$83.94M 10-Q · filed 2021-08-05 | |
| 2019-12-31 | -$64.89M 10-K · filed 2022-03-10 | |
| 2019-09-30 | -$47.02M 10-Q · filed 2020-11-25 | |
| 2019-06-30 | -$33.37M 10-Q · filed 2020-11-25 | |
| 2018-12-31 | -$13.75M 10-K · filed 2021-03-23 | -$13.75M 10-Q · filed 2020-11-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |